Trovagene

TROV NASDAQ
3.130
+0.050
+1.62%
Opening 11:18 05/20 EDT
Open
3.120
Prev Close
3.080
High
3.140
Low
3.100
Volume
23.44K
Avg Vol (3M)
1.19M
52 Week High
20.26
52 Week Low
2.536
% Turnover
0.45%
Market Cap
16.35M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Trovagene TROV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
MORE >

Recently

Name
Price
%Change